Roche results. London, 28 January 2015

Transcription

1

2 Roche 2014 results London, 28 January 2015

3 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected. 3

4 Group Severin Schwan Chief Executive Officer 4

5 2014 performance Outlook 5

6 2014: Targets achieved Targets for 2014 FY 2014 Group sales Low to mid-single digit growth 1 +5% Core EPS Ahead of sales growth 1 +5% +7% excl. one-time US Pharma fee 2 Dividend Further increase dividend 3 CHF % 1 At constant exchange rates 2 One-time double charge of CHF 202m for the US Branded Prescription Drug fee in 2014, following final regulations issued by the US Internal Revenue Service which advanced the timing of recording the liability dividend as proposed by the Board of Directors 6

7 2014: Highlights Growth Group sales +5% 1 driven by HER2 franchise (+20% 1 ), Avastin (+6% 1 ), Actemra (+23% 1 ) and Professional Diagnostics (+8% 1 ) Outperformance in all major regions: +6% 1 in US, Japan & International; +3% 1 in Europe Innovation Three Breakthrough Therapy Designations: Anti-PDL1, Esbriet and Lucentis Three Fast Track Designations: Lampalizumab, cobimetinib and LptD (antibiotic) Cancer immunotherapy: New PD-L1 data in bladder, TNBC, renal. Six new agents entered clinic Phase 3 starts: Lampalizumab, etrolizumab, alectinib, venetoclax and Kadcyla adjuvant Launched next generation molecular diagnostics platform (cobas 6800/8800) M&A InterMune: Acquisition completed Foundation Medicine: Collaboration announced 1 CER=Constant Exchange Rates 7

8 First take on Swiss National Bank`s decision On January 15, the Swiss National Bank (SNB) announced its decision to unpeg the Swiss franc from the Euro Natural hedge of the underlying business: 18% of operating costs in Switzerland US, Europe, Japan and China with complete value chain Interest expenses predominantly paid in USD 2015 dividend payout for March converted prior to SNB decision 8

9 2014: Solid sales growth Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division Diagnostics Division Roche Group CER=Constant Exchange Rates 9

10 2014: Continued sales growth for 4 years 10% 8% 6% 6% 6% 6% 8% 7% 5% 5% 6% 4% 4% 4% 4% 4% 2% 2% 0% 0% 0% 1% Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 All growth rates at Constant Exchange Rates (CER) 10

11 2014: Both Divisions with sales growth in all regions CHFbn % +4% +3% +6% +2% +13% +6% +6% +3% 0% +2% +7% Japan International Europe US Diagnostics Pharma All growth rates at Constant Exchange Rates (CER) 11

12 2014: Group core operating profit & margin remains at high levels 34.9% 35.6% 37.7% 38.3% 37.2% (37.6%*) +3% at CER (+5%*) % of sales CHFbn CER=Constant Exchange Rates * Excluding one-time double charge for the US Branded Prescription Drug fee in

13 2014: Core EPS growth bridge +1.7% +6.9% +5.2% one-time US Pharma fee* +4.9% Sales Core EPS Full Year 2014 figures as reported Core EPS Full Year 2014 excl. one-time US Pharma fee* CER=Constant Exchange Rates * Excluding one-time double charge for the US Branded Prescription Drug fee in

14 2014: Dividend and payout ratio further increased CHF payout ratio: 56.0% Dividend payout ratio (%) Payout ratio calculated as dividend per share divided by core earnings per share (diluted); 2014 dividend as proposed by the Board of 1 Directors; compound Note: annual For 1995, growth a special rate dividend was paid out to mark F. Hoffmann-La Roche s 100th anniversary in

15 Roche: A pipeline of differentiated products Oncology Launched Avastin Rituxan/MabThera Herceptin Xeloda Tarceva Zelboraf Erivedge Perjeta Kadcyla Gazyva/Gazyvaro Immunology/ Ophthalmology Esbriet Pulmozyme Xolair Actemra/RoActemra Rituxan/MabThera RA Lucentis Oncology Neuroscience Ophthalmology Immunology Phase III pictilisib 1 taselisib 1 anti-pdl1 venetoclax (Bcl2i) cobimetinib 4 alectinib lebrikizumab etrolizumab 2 lampalizumab 3 Neuroscience ocrelizumab gantenerumab Phase II 10 NMEs + 9 AIs 3 AIs 6 NMEs 1 Phase III decision pending; 2 FPI in 1H 2014; 3 FPI in 2H 2014; 4 Filed in combination with Zelboraf in metastatic melanoma AI = Additional Indication; NME = New Molecular Entity 15

16 2014 performance Outlook 16

17 2015 milestones Launch new products Expand cancer immunotherapy Esbriet: US and EU Cobimetinib + Zelboraf: US and EU PD-L1: Bladder, Lung, Renal, Triple Negative BC NMEs: OX40, CD40, CEA-IL2, CSF1R, IDO, CEA-CD3 Renew CD20 franchise Gazyva (aggressive NHL)* Entry into Hemophilia ACE910: Start of pivotal trials Entry into Multiple Sclerosis Ocrelizumab: Phase 3 readout Diagnostics Rollout of key platforms (cobas 6800 / 8800) * Event-driven (interim analysis) 17

18 2015 outlook Group sales growth 1 Low to mid-single digit Core EPS growth 1 Ahead of sales growth 2 Dividend outlook Further increase dividend in Swiss francs 1 At constant exchange rates 2 Excluding sale of filgrastim rights in

19 Pharmaceuticals Division Daniel O Day COO Roche Pharmaceuticals 19

20 2014 results Innovation Outlook 20

21 2014: Pharma sales All regions with positive growth Change in % CHFm CHFm CHF CER Pharmaceuticals Division 36,696 36, United States 15,822 15, Europe 9,422 9, Japan 3,301 3, International 8,151 8, CER=Constant Exchange Rates 21

22 2014: Pharma Division Investment in Esbriet launch 2014 CHFm % sales Sales 36, Excl. 340B: +5% 2014 vs CER growth 4% Royalties & other op. inc. 2, Cost of sales -7, M & D -5, R & D -7, G & A -1, Excl. filgrastim deal: +10% Esbriet launch PSI Excl. & PSI & US US Pharma Pharma fee*:+14% 4% 4% 6% 35% 50% Core operating profit 16, % -1% in CHF CER=Constant Exchange Rates * Refers to 2013 past service income of CHF 131m and one-time double charge for the US Branded Prescription Drug fee in

23 2014: Pharma sales HER2, Avastin and Tamiflu main growth drivers Perjeta +189% Herceptin Avastin Tamiflu Kadcyla Actemra/RoActemra Xolair +7% +6% +54% +135% +23% +25% MabThera/Rituxan Pegasys Xeloda -46% -20% +2% US Europe Japan International CHFm Absolute amounts and growth rates at Constant Exchange Rates (CER) 23

24 2014: Oncology sales up +5% Perjeta CER growth HER2 MabThera/ Rituxan Avastin Herceptin +20% Kadcyla +2% +6% +20% Strong uptake of Perjeta & Kadcyla Increased usage across a variety of indications Growth despite 340B baseline effect and Russia Continued uptake in ovarian & cervical (US) Treatment through multiple lines in CRC Tarceva -1% In-class competition Xeloda -46% Loss of exclusivity Zelboraf CHFbn -12% Competitive pressure in US & EU Potential approval of cobrim in 2015 CER=Constant Exchange Rates 2014 Oncology sales: CHF 22.8bn 24

25 Avastin: Growth supported by recent launches CHFm YoY CER growth 7,000 6,000-7% +6% +6% +13% Platinum-resistant ovarian cancer Launched in US and EU 5,000 Cervical cancer 4,000 Launched in US and filed in EU 3,000 2,000 HER2 negative breast cancer Positive phase 3 data in treatment through multiple lines (TML) and 1L 1, US Europe International Japan Colorectal cancer CALGB H2H data support standard of care in 1L CER=Constant Exchange Rates 25

26 HER2 franchise: Strong growth driven by Perjeta and Kadcyla CHFm 2,500 YoY CER growth 2,000 1,500 16% 10% 15% 7% 15% 20% 17% 23% 23% 19% Kadcyla 1,000 Perjeta Herceptin Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 CER=Constant Exchange Rates 26

27 Immunology products: Accelerated growth Driven by Actemra SC and Xolair CHFm % 19% YoY CER growth % 18% 18% 20% 15% 18% Actemra SC 400 Actemra IV Xolair Pulmozyme Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 CER=Constant Exchange Rates 27

28 Lucentis: Flattening in a competitive environment Breakthrough designation in Diabetic Retinopathy Lucentis sales (USDm) Growth driven by DME and continued market expansion Eylea wamd Q3 11 Q4 11 Q1 12 Q2 12 Lucentis DME Q3 12 AMD Less-frequent than monthly dosing Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Outlook Increased competition in AMD and DME Breakthrough Status and Priority Review for treatment of DR (PDUFA date Feb 6) AMD=wet age-related macular degeneration; DME=diabetic macular edema; DR=diabetic retinopathy 28

29 Esbriet strong launch CHFm Esbriet sales US launch off to strong start FDA approval on 15 October 2014, patients still in transition to full reimbursement Q Q Q3 13 Q4 13 Q3 Q Q2 14 Q3 14 Q4 14 > 1,300 patients in clinical trials European sales with strong growth EU label strengthened to include the ASCEND and pooled one year mortality data on October 23, 2014 Europe Canada US Europe Canada US Sales based on average 2013 exchange rate 29

30 2014 results Innovation Outlook 30

31 2014: Major clinical and regulatory news flow Regulatory Phase III Phase III starts Compound Indication Milestone Actemra SC Rheumatoid arthritis EU approval Avastin Glioblastoma EU approval Avastin Cervical cancer US, EU filing Avastin Pt-resistant ovarian cancer US, EU approval MabThera SC NHL EU approval Gazyvaro Front line CLL EU approval Xolair Chronic idiopathic urticaria US approval Esbriet Idiopathic pulmonary fibrosis US approval oral octreotide Acromegaly Ph III cobimetinib BRAF+ met. melanoma Ph III (co-brim) gantenerumab Prodromal Alzheimer`s disease Ph III (SCarlet RoAD) Kadcyla/Perjeta 1L met. HER2+ breast cancer Ph III (MARIANNE) Esbriet Idiopathic pulmonary fibrosis Ph III (ASCEND) Kadcyla Adjuvant HER2+ breast cancer Ph III (KAITLIN) Kadcyla Neo-adjuvant HER2+ breast cancer Ph III (KRISTINE) venetoclax (Bcl2 inh.) Relapsed/refractory CLL Ph III (MURANO) Anti-PDL1 2/3L NSCLC Ph III (OAK) alectinib ALK+ NSCLC Ph III (ALEX) etrolizumab Ulcerative colitis Ph III (HIBISCUSI/II, GARDENIA, LAUREL, HICKORY, COTTONWOOD) gantenerumab Mild Alzheimer`s disease Ph III (Marguerite RoAD) lampalizumab Geographic atrophy Ph III (CHROMA, SPECTRI) 31

32 Roche: A pipeline of differentiated products Oncology Launched Avastin Rituxan/MabThera Herceptin Xeloda Tarceva Zelboraf Erivedge Perjeta Kadcyla Gazyva/Gazyvaro Immunology/ Ophthalmology Esbriet Pulmozyme Xolair Actemra/RoActemra Rituxan/MabThera RA Lucentis Oncology Neuroscience Ophthalmology Immunology Phase III pictilisib 1 taselisib 1 anti-pdl1 venetoclax (Bcl2i) cobimetinib 4 alectinib lebrikizumab etrolizumab 2 lampalizumab 3 Neuroscience ocrelizumab gantenerumab Phase II 10 NMEs + 9 AIs 3 AIs 6 NMEs 1 Phase III decision pending; 2 FPI in 1H 2014; 3 FPI in 2H 2014; 4 Filed in combination with Zelboraf in metastatic melanoma AI = Additional Indication; NME = New Molecular Entity 32

33 HER2 franchise expected to grow further Biosimilars delayed to 2017 Est. Biosimilars launch (EU) 2nd line mbc Xeloda + lapatinib Kadcyla (EMILIA) 1st line mbc Herceptin + chemo Herceptin & Perjeta + chemo (CLEOPATRA) Adjuvant BC Herceptin + chemo Herceptin sc + chemo (HannaH) Herceptin & Perjeta + chemo (APHINITY) Kadcyla (KATHERINE) Neoadjuvant BC Herceptin + chemo (NOAH) 1 Herceptin & Perjeta + chemo (Neosphere, Tryphaena) 2 Kadcyla & Perjeta + chemo (KRISTINE) Kadcyla & Perjeta (KAITLIN) Established standard of care New standard of care Potential new standard of care Key priorities in 2015 Strengthen PERJETA as standard of care in 1L mbc & neoadjuvant, Kadcyla in 2L Secure durable conversion from Herceptin IV to SC Clinical data in 2015 PERJETA 2L PHEREXA final PFS & interim OS data expected Q3 15 Release of the NEOSPHERE final PFS/DFS data at ASCO 33

34 Hematology franchise Extensive late stage clinical trial program Biosimilars delayed to 2017 Compound Combination Indication P 1 P 2 P 3 Gazyva Mono GREEN R/R CLL Gazyva Mono GOYA anhl Gazyva Mono GADOLIN inhl Gazyva Mono GALLIUM 1L FL Gazyva +PDL1 R/R FL Gazyva +PDL1 anhl venetoclax* +Rituxan MURANO R/R CLL venetoclax +Gazyva CLL14 CLL venetoclax Mono R/R CLL 17p venetoclax +Rituxan R/R FL venetoclax Mono 1L anhl venetoclax Mono R/R NHL venetoclax Mono R/R MM venetoclax Mono AML polatuzumab +Rituxan/Gazyva NHL polatuzumab +Gazyva R/R FL polatuzumab +Gazyva anhl * Partnered with AbbVie venetoclax (Bcl2 inhibitor); polatuzumab vedotin (CD79b ADC) 34

35 Anti-PDL1 in triple negative breast cancer Encouraging early data TNBC a PD-L1 IHC (IC) n ORR, Best Response, b % (95% CI) PD-L1+ vs PD-L1- ORR, b % (95% CI) IHC % (1,60) IHC % (14,98) 33% (10,70) IHC IHC Encouraging efficacy in monotherapy Well tolerated Update at a medical conference in 2015 Emens LA, et al. SABCS,

36 2014 Roche cancer immunotherapy: Six NMEs moved into the clinic Priming & activation Anti-CEA-IL2v Anti-OX40 NME (Anti-ctyokine) Anti-CD27* T cell Trafficking T cell infiltration Anti VEGF: Avastin New in 2014 Antigen presentation Anti-CD40 IMA942 vaccine* (Immatics) Cancer T cell recognition Anti-CEA-CD3 Anti-HER2-TDB Antigen/T cell bispecific Mabs ImmTAC* (Immunocore) Clinical development Preclinical development Established therapies * Partnered projects (external) Chen and Mellman. Immunity 2013 Antigen release Targeted therapies: Tarceva, cobimetinib, Zelboraf, Gazyva T cell killing Anti-PD-L1 Anti-CSF-1R Anti-CEA-IL2v Anti-OX40 IDO inhibitor (NewLink Genetics) NME (undisclosed) IDO inhibitor* (Incyte) 36

37 Cancer immunotherapy program growing strongly Compound Combination Indication Ph 1 Ph 2 Ph 3 PDL1 Mono +Tarceva Lung PDL1 Mono Bladder PDL1 PDL1 PDL1 Mono +Avastin +Zelboraf +Zelboraf+cobimetinib Mono +Avastin +cobimetinib +ipilimumab +IFN alfa-2b +CD40 +OX40 +CSF-R1 +CEA IL2v Renal Melanoma Solid tumors PDL1 +Avastin+FOLFOX Colorectal PDL1 Mono +Gazyva Hematology PDL1 Mono Triple negative breast cancer CSF-1R Mono +CD40 Solid tumors CEA IL-2v Mono Solid tumors OX40 Mono Solid tumors CEA CD3 Mono Solid tumors IDO Mono Solid tumors Study ongoing Study imminent Additions since Q3 Status as at January

38 Roche cancer immunotherapy Pipeline as of 2014 year end Anti-PDL1+Tarceva NSCLC Anti-PDL1+Zelboraf Melanoma Anti-PDL1 Solid tumors Anti-PDL1+Avastin Solid tumors Anti-PDL1+cobimetinib Solid tumors Anti-PDL1+ipilimumab Solid tumors Anti-PDL1+IFN-alfa Solid tumors Anti-PDL1+ CD40 Solid tumors PDL1+Avastin+FOLFOX CRC Anti-PDL1 + Gazyva Blood cancer Anti-PDL1 TNBC Anti-CSF1R Solid tumors Anti-CEA IL-2v Solid tumors Phase I Status as at December 2014 Anti-OX40 Solid tumors CEA CD3 Solid tumors IDO Solid tumors Anti-PDL1 trials NMEs monotherapy Immune doublets Phase II Anti-PDL1 NSCLC (Dx+) Anti-PDL1 NSCLC 2/3L Anti-PDL1+Avastin Renal 1L Anti-PDL1 Bladder 1/2L Phase III Anti-PDL1 NSCLC 2/3 L 38

39 Roche cancer immunotherapy and additional trials already decided upon Anti-PDL1+Tarceva NSCLC Anti-PDL1+Zelboraf Melanoma Anti-PDL1 Solid tumors Anti-PDL1+Avastin Solid tumors Anti-PDL1+cobimetinib Solid tumors Anti-PDL1+ipilimumab Solid tumors Anti-PDL1+IFN-alfa Solid tumors Anti-PDL1+ CD40 Solid tumors PDL1+Avastin+FOLFOX CRC Anti-PDL1 + Gazyva Blood cancer Anti-PDL1 TNBC Anti-CSF1R Solid tumors Anti-CEA IL-2v Solid tumors Phase I Status as at January 28, 2015 Anti-OX40 Solid tumors CEA CD3 Solid tumors IDO Solid tumors Anti-PDL1 + OX40** Solid tumors Anti-PDL1 + CSF1R** Solid tumors Anti-PDL1 + CEA-IL2v** Solid tumors Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba ** Anti-PDL1 trials NMEs monotherapy Immune doublets 2015 readout expected Study start in 2015 Phase II Anti-PDL1 NSCLC (Dx+) Anti-PDL1 NSCLC 2/3L Anti-PDL1+Avastin Renal 1L Anti-PDL1 Bladder 1/2L Phase III Anti-PDL1 NSCLC 2/3 L Anti-PDL1** Bladder 2L Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba 39

40 Oncology Molecular Information How we will collaborate with Foundation Medicine Roche/FMI R&D Collaboration 1. Comprehensive tumor analysis in Roche Clinical Trials DNA & RNA sequencing 2. We will innovate together Immunotherapy Panel Blood based continuous monitoring What we aim to achieve together Key initial areas for collaboration Cancer Immunotherapy test Continuous monitoring test Brings together expertise needed to innovate for patients Roche a leader in PHC/companion diagnostics across modalities FMI a leader in comprehensive genomic profile development and molecular information 40

41 INHIBITOR NON-INHIBITOR ACE 910 in Hemophilia A A novel FVIIIa mimetic bispecific antibody FVIIIa On-demand treatment 1-3 times/bleeding event, IV Prophylaxis 3 times/week, IV Inhibiting Factor VIII antibodies in 20-33% of the patients ACE 910 Immune Tolerance Induction % success rate limitation due to very high cost and heavy burden for patients Kitazawa, Shima, Yoshioka, Hattori. Nature Medicine 2012;18(10):1570, Sampei, et al. PLoS One 2013;8(2):e57479, Muto, Shima, Hattori. J Thromb Haemost 2014;12:206 On-demand treatment with bypassing agents 2-3h intervals, IV Prophylaxis with bypassing agents Every other day, IV Mode of action Novel approach promoting FX activation and acceleration of coagulation Targeted product profile Less frequent dosing Subcutaneous Avoid induction of inhibiting antibodies In collaboration with Chugai 41

42 2014 results Innovation Outlook 42

43 2015: Key late-stage news flow Compound Indication Milestone Regulatory Phase III readouts* Phase III starts Phase II readouts* Avastin Cervical cancer EU approval Lucentis Diabetic retinopathy US approval alectinib ALK+ NSCLC US filing Cobimetinib + Zelboraf 1L Melanoma US, EU approval Gazyva Front line anhl Ph III GOYA (interim) ocrelizumab Relapsing MS (RMS) Ph III OPERA I/II ocrelizumab Primary progressive MS (PPMS) Ph III ORATORIO Perjeta 2L HER2+ mbc Ph III PHEREXA Kadcyla HER2+ gastric cancer Ph II/III GATSBY Anti-PDL1 Bladder Ph III Anti-PDL1 Tumor type 1 Ph III Anti-PDL1 Tumor type 2 Ph III Anti-PDL1 Tumor type 3 Ph III Etrolizumab Crohn`s disease Ph III ACE910 Hemophilia A Ph III taselisib (PI3K inhib) HR+/PI3Kmut BC Ph III SANDPIPER Anti-PDL1 2/3L NSCLC Ph II FIR, POPLAR, BIRCH Anti-PDL1 Bladder Ph II ipatasertib (AKT inhib) Gastric/prostate cancers Ph II A.MARTIN, JAGUAR * Outcome studies are event driven, timelines may change 43

44 Diagnostics Division Roland Diggelmann COO Roche Diagnostics Picture 44

45 2014: Diagnostics Division sales Growth driven by Professional Diagnostics Change in % CHFm CHFm CHF CER Diagnostics Division 10,766 10, Professional Diagnostics 6,045 5, Diabetes Care 2,392 2, Molecular Diagnostics 1,613 1, Tissue Diagnostics Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +8% CER=Constant Exchange Rates 45

46 2014: Diagnostics regional sales Growth driven by APAC and EMEA North America +4% 25% of divisional sales EMEA 1 +4% 45% of divisional sales Japan 0% 4% of divisional sales Latin America +13% 7% of divisional sales Asia Pacific +15% 19% of divisional sales 16% growth in E7 countries 2 1 Europe, Middle East and Africa; 2 Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at constant exchange rates 46

47 2014: Diagnostics Division Profit growth in line with sales excl. PSI* vs CHFm % sales CER growth Sales 10, % Royalties & other op. inc Cost of sales -4, M & D -2, R & D -1, G & A Excl. VAT*: +8% Admin: +6% Excl. PSI*: +5% 2% 9% 4% 3% Excl. VAT*: +8% 21% Core operating profit 2, Excl. PSI*: +5% and VAT*: +8% 2% -4% in CHF CER=Constant Exchange Rates * PSI: 2013 past service income of CHF 67m; VAT: 2013 one-time VAT refund of CHF 45m 47

48 2014: Diagnostics Growth driven by Professional Diagnostics CER growth Professional Dia +8% Continued double digit growth in immunodiagnostics (+13%) Further expansion of leading menu Diabetes Care +1% Accu-Chek Aviva/Performa (+7%) and Mobile (+19%) Molecular Dia 1 +6% Virology (+7%) incl. HPV (+48%) Launch of cobas 6800/8800 systems with assays for blood screening and virology Tissue Dia Sales CHFbn +10% EMEA North America RoW Advanced staining portfolio (+9%) and companion diagnostics (+27%) 1 Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +8% CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa 48

49 Serum work area (42% of sales)* Growing strongly in all regions Integrated SWA * solution Immunodiagnostics (+13%) Clinical chemistry (+7%) +10% +8% +15% +8% Japan Latin America North America +19% Asia-Pacific +5% EMEA *SWA: serum work area: clinical chemistry and immunodiagnostics 49

50 Invest for growth New reagent manufacturing in China RPD reagent volume Asia Other x2 Reliable local supply and right sizing of cost base Reagent formulation, filling and packaging Packaging to begin in 2016 Fully operational in E 2022E RPD = Roche Professional Diagnostics 50

51 Extend leading menu in women s health High prognostic value of preeclampsia blood test Assay and claim extension Extends the applicability of the assay from 3-5% of pregnancies to 20% Fully automated Test performed across entire cobas analyzer platform series * Hund, M., et al. (2014) BMC Pregnancy and Childbirth 14, 324; Zeisler, H.,. et al. (2014) XX COGI World Congress 2014 *Preeclampsia can be ruled-out for 1 week after testing 51

52 Molecular Diagnostics Launch and implementation of cobas 6800/8800 High Throughput Reference Labs cobas 8800 Advanced PCR automation Highest throughput (3x above closest competitor) CE launch of blood screening and virology assays Large Hospitals cobas 6800 Medium Hospitals cobas 4800 Low to middle volume throughput Broadest menu incl HPV testing Low Throughput 52

53 Entering Molecular Point of Care Diagnostics Acquisition of IQuum, launch of cobas Liat analyzer Liat Analyzer Liat tube Target market: ~CHF 350m, growing ~20% p.a. Laboratory in a tube technology: Fast and easy to use CLIA waiver expected in 2015 Portfolio: Influenza A/B and Strep A test, CE marked and FDA cleared Plans to extend menu in: Respiratory Syncytial Virus tests MRSA and C-difficile Point of Care: e.g. physician s office, emergency rooms, ambulance, pharmacies; MRSA: methicillin resistant Staphilococcus aureus 53

54 Sequencing strategy Building a leading sequencing solution Grow through disruptive innovation Sample preparation Developing complete sequencing solutions Testing platform Menu of assays Data analysis Reporting Abvitro: Technology acquisition; Ariosa: Acquisition; Genia: Acquisition; Pacific Biosciences: Partnership; Bina: Acquisition; Foundation Medicine: Partnership 54

55 Sequencing menu: Non-invasive prenatal testing Acquisition of Ariosa Harmony TM Prenatal Test Target market USD 400m sales worldwide in 2013, +30% pa Technology Analyses fetal DNA with microarray technology Highly cost effective and accurate Screens for the risk of Down, Edwards and Patau syndrome Digital analysis of selected regions (DANSR TM ) technology Strategy Expand market access through kit distribution model Add test to Roche sequencing platform when available 55

56 Key launches 2014 Instruments / Devices Tests / Assays Area Product Market BA 1 Labs Diabetes Care Infectious Diseases / Blood Screening Microbiology Women s Health cobas 6800/8800 Next generation molecular (PCR) system cobas m 511 Fully integrated and automated hematology system cobas 6500 Automated urinalysis work area platform Connect-V Middleware providing connectivity to LIS 2 Accu-Chek Insight- Next generation insulin pump & bgm 3 system Accu-Chek Connect bg meter with connectivity to smart phones, mobile App and cloud MPX 2.0 Next generation blood screening multiplex test MPX (HIV, HCV, HBV), HEV, DPX 4, WNV 5 Full NAT blood screening menu for cobas 6800/8800 HIV, HCV, HBV Virology tests for cobas 6800/8800 HSV- Detection of Herpes Simplex Virus on cobas 4800 Syphilis Immunoassay for the detection of Treponema pallidum MRSA/SA Next generation assay on cobas 4800 C-difficile Diagnosis of infections and associated diarrhea PE Prognosis- Claim extension for short-term prediction of Preeclampsia in pregnancy AMH- Assessment of ovarion reserve for fertility WW* EU EU WW EU EU US WW* WW* EU EU EU EU EU EU RMD RPD RPD RTD RDC RDC RMD RMD RMD RMD RPD RMD RMD RPD RPD * Excluding US; 1 Business Areas: RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics, RTD: Roche Tissue Diagnostics; 2 hospital information systems; 3 blood glucose monitoring; 4 parvovirus B19 and hepatitis A virus; 5 west nile virus 56

57 Key launches 2015 Instruments / Devices Tests / Assays Area Product Market BA 1 Laboratory Diabetes Care cobas c 513 dedicated HbA1C analyzer cobas t 411 core lab coagulation analyzer cobas 8100 V2 Integrated pre- and post-analytical solution cobas 6800/8800 Medium to High volume automated real-time PCR VENTANA HE 600 automated H&E staining platform Accu-Chek Active no-code next-gen. bg meter, no coding of test strips Accu-Chek Connect bg meter with connectivity to smartphones, mobile applications and cloud Point of Care CoaguChek Pro II - professional system for PT and aptt testing EU RPD Blood Screening Infectious Diseases Virology Genomics & Oncology EU EU WW US WW WW US RPD RPD RPD RMD RTD RDC RDC cobas 6800/8800 MPX Multiplex Bloodscreening test US RMD cobas Liat Influenza A/B + RSV POC detection HTLV human T-lymphotropic virus diagnostics test cobas 6800/8800 HBV Quantitative HBV viral load test cobas 4800 HIV-1 - Quantitative HIV viral load test cobas 4800 HCV Quantitative HCV viral load test cobas 4800 HBV Quantitative HBV viral load test US EU EU EU EU EU RMD RPD RMD RMD RMD RMD cobas EGFR Test v2 - detection of EGFR in plasma EU RMD Cardiac Cobas h 232 Troponin T Point of Care test version of Elecsys ctnt-hs EU RPD 1 Business Areas. RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics; RTD: Roche Tissue Diagnostics; 57

58 Outlook Investing into future growth Continued strong growth in serum work area Focus on implementation of next generation platforms, e.g. cobas 6800/8800 Continued investment into development of future sequencing solution Ongoing structural adjustments in Diabetes Care to adapt to continuing challenging market environment Strengthen leading presence in emerging markets 58

59 Finance Alan Hippe Chief Financial Officer 59

60 2014: Highlights Business Solid sales and Core EPS growth: +5% 1 ; Core EPS +7% 1 excluding US Pharma fee* Core operating profit up +3% 1 or +5% 1 excluding US Pharma fee* Cash generation remains strong with operating FCF of CHF 15.8bn, a decrease of -2% 1 due to higher capital investments Accounts receivable in Southern Europe further decreased Improved financial result and major currency impact Positive development of Core Net Financial result: +32% 1 due to sale of equities and lower interest expenses Increased net debt due to acquisitions Group currency exposure solid natural hedge, 82% of cost base outside Switzerland 1 CER=Constant Exchange Rates * Excluding one-time double charge for the US Branded Prescription Drug fee in

61 2014: Group currency exposure Overall solid natural hedge Currency exposure 50% Sales Operating costs 40% 41% 38% 30% 28% 20% 18% 21% 17% 21% 10% 0% 8% 6% 2% CHF USD EUR JPY Others FY 2014 currency structures; operating costs include all items between the sales and the operating profit lines 61

62 2014 performance Focus on cash 62

63 2014: Group performance Core EPS growth +5% 1 or +7% 1 excl. US Pharma fee* Change in % Excl. US CHFm CHFm CHF CER Pharma fee* Sales 47,462 46, Core operating profit 17,636 17, as % of sales Core net income 12,533 12, as % of sales Attributable to Roche shareholders 12,329 12, Core EPS (CHF) Operating free cash flow 15,778 16, as % of sales Free cash flow 5,322 5, as % of sales CER=Constant Exchange Rates * Excluding one-time double charge for the US Branded Prescription Drug fee in

64 2014: Group operating performance Core OP growth +3% 1 or +5% 1 excl. US Pharma fee* vs CHFm % sales CER growth Sales 47, % Royalties & other op. inc. 2, Cost of sales -12, M & D -8, R & D -8, G & A -2, Excl. filgrastim deal: +10% Excl. PSI and US Pharma fee*:+8% 6% 6% 4% 33% 38% Core operating profit 17, Excl. US Pharma fee*: +5% 3% -1% in CHF 1 CER=Constant Exchange Rates * US Pharma fee: one-time double charge for the US Branded Prescription Drug fee in 2014; PSI: 2013 past service income of CHF 302m 64

65 2014: Core operating profit and margin Margin at high levels CHFm 37.7% 38.3% 37.2% 17,160 17, % 1 (-1 %) 17,636 (-0.1%p 2 ) -0.5 %p 1 (-1.1 %p) 44.0% 44.4% 43.6% 15,488 16, % 1 (-1 %) 16,001 (+0.3%p 2 ) -0.2 %p 1 (-0.8 %p) % of sales 21.3% 20.8% 19.5% -0.9 %p 1 (-1.3 %p) ,187 2, % 1 (-4 %) 2,096 Roche Group Pharma Division Diagnostics Division 1 CER=Constant Exchange Rates 2 At CER excluding one-time double charge for the US Branded Prescription Drug fee in

66 2014: Core net financial result Higher income from equities and lower interest expenses CHFm ,000-1,500-1,699 Improvement of 34% in CHF / 32% at CER ,116-2, Net income Interest FX All other, net 2014 from equity expense gains/losses securities CER=Constant Exchange Rates 66

67 Balance sheet 31 December 2014 Equity ratio at 29% due to acquisitions CHFbn CHFbn Cash and marketable securities Other current assets Non-current assets % Current liabilities % % 26% 25% % Non-current liabilities 41% 40% % % Equity (Net assets) 34% 29% Net debt/ total assets: 19% 31/12/13 31/12/14 31/12/13 31/12/14 Assets Equity & liabilities CER=Constant Exchange Rates 67

68 2014: Group core tax rate Double R&D tax credits in 2013 Figures in % Relative higher core profits in US US R&D tax credits for 2012 and 2013, included in 2013 while only one year credits in Profit mix US

69 2014 performance Focus on cash 69

70 2014: Operating free cash flow remains at high levels CHFm 35.5% 35.0% 33.2% 41.8% 41.3% 40.4% 16,135 16, %p 1 (-1.8 %p) -2 % 1 (-4 %) 15,778 14,710 14, %p 1 (-0.9 %p) 0 % 1 (-1 %) 14, % 18.7% % of sales 13.2% -5.3 %p 1 (-5.5 %p) ,890 1, % 1 (-28 %) 1,417 Roche Group Pharma Division Diagnostics Division CER=Constant Exchange Rates 70

71 2014: Accounts receivable in Southern Europe further decreased B BB Greece Portugal Dec 2014 Dec 2013 Dec 2012 Dec 2011 BBB- Italy BBB Spain ,036 Southern European Countries 1,171 1,645 1,836 2,462-52% ,200 1,600 2,000 2,400 2,800 CHFm 1 CER=Constant Exchange Rates Note: Sovereign country ratings from Standard & Poor s, as of 7 January

72 2014: Group net debt development Higher net debt due to InterMune acquisition CHFbn Free Cash Flow CHF 5.3bn 1% (CER) higher than Dividends -6.7 Taxes -3.0 Treasury -0.8 Business comb Own equities -0.8 Other -2.2 Net debt 31 Dec 2013 Operating Free Cash Flow Non-op. FCF Business combinations, Currency translation & other Net debt 31 Dec 2014 CER=Constant Exchange Rates 72

73 Balance sheet: Net debt to total assets Ratio higher than 2013 due to InterMune acquisition Net debt / total assets 16% 11% 19% 75.6 Total assets (CHFbn) Net debt (CHFbn) Dec Dec Dec

74 December 2014: Debt maturity profile Balanced maturity profile CHFbn 5 4 GBP CHF EUR USD Of the CHF 48 bn bonds and notes issued to finance the Genentech transaction, cumulative CHF 36 bn have been repaid as of December 31, 2014* Nominal actual FX rates; *Original net proceeds in CHF 74

75 Currency impact on Swiss franc results 2014 Negative currency impact CHF / USD Average YTD % % Assumed average YTD % -4% -1% +1% In 2014 impact is (%p): Monthly avg fx rates 2014 Fx rates at 31 Dec 2014 J F M A M J J A S O N D CHF / EUR % -1% % +2% 0% +2% Q1 HY Sep YTD FY Sales Core operating profit -8-4 Core EPS J F M A M J J A S O N D 75

76 Currency sensitivities for 2014 Impact of 1% change in average exchange rate vs. the Swiss franc Figures in CHFm Sales Core OP US dollar Euro Japanese yen All other currencies

77 2015 outlook Group sales growth 1 Low to mid-single digit Core EPS growth 1 Ahead of sales growth 2 Dividend outlook Further increase dividend in Swiss francs 1 At constant exchange rates 2 Excluding sale of filgrastim rights in

78

79 Changes to the development pipeline FY 2014 update New to Phase I New to Phase II New to Phase III New to Registration 11 NMEs RG6047 SERD (2) ER-pos (HER2- neg) mbc RG6078 IDO inh - solid tumors RG7802 CEA CD3 TCB - solid tumors RG7876 CD40 imab+pd-l1 MAb - solid tumors RG7787 MSLN-PE cfp solid tumors RG7689 NME infectious diseases RG7880 NME - autoimmune diseases RG7625 NME - autoimmune diseases RG6080 DBO β-lactamase inh - bacterial infections RG7345 TAU ps422 MAb AD RG7597 HER3/EGFR DAF+cobimetinib KRAS mutation-pos tumors 2AIs RG7155 CSF-1R+PD-L1 MAb - solid tumorssolid tumors RG7446 PD-L1 MAb + Gazyva lymphoma 2NMEs transitioned from Ph1 RG6046 SERD ER-pos (HER2-neg) mbc CHU: URAT 1 inh - gout 5 AIs RG3502 Kadcyla HER2-pos advanced NSCLC RG435 Avastin + Tarceva - EGFR mutpos. NSCLC RG6062 Esbriet ILD, systemic sclerosis related RG7421 cobimetinib triple negative breast cancer RG7601 venetoclax (Bcl-2-inh)+ Rituxan - rel/ref follicular lymphoma 3 AIs RG7601 venetoclax (Bcl-2 inh)+ Gazyva - CLL 1 st line RG7446 PD-L1 bladder cancer 2nd line CHU Actemra large-vessel vasculitis (added by Chugai) 1 AI following EU submission RG105 MabThera CLL subcutaneous formulation Removed from Phase I Removed from Phase II Removed from Phase III Removed from Registration 3 NMEs RG7666 PI3K inh - glioblastoma 2L RG7624 IL-17 MAb - autoimmune diseases RG7458 MUC16 ADC - ovarian and pancreatic cancer Status as of January 28, NMEs RG7593 pinatuzumab vedotin (CD22 ADC) - heme tumors RG7449 quilizumab - asthma RG7128 mericitabine - HCV RG1512 inclacumab - ACS/CVD RG1578 decoglurant (mglur2 NAM) - depression RG7597 HER3/EGFR DAF m. epithelial tumors 1 AI removed by Chugai Suvenyl - enthesopathy 1 AI following US approval RG435 Avastin - rel. ovarian ca. Ptresistant 79

80 Roche Group development pipeline Phase I (33 NMEs + 11 AIs) Oncology Other disease areas RG6016 LSD1 inh AML RG7625 autoimmune diseases RG6047 SERD (2) ER+(HER2-neg) mbc RG autoimmune diseases RG6061 HIF1 alpha LNA solid tumors RG6080 DBO β-lactamase inh bact. infections RG6078 IDO inh solid tumors RG infectious diseases RG7116 HER3 MAb solid tumors RG7795 TLR7 agonist HBV RG7155 CSF-1R + PDL-1 MAb solid tumors RG7641 aldosterone synth inh met. diseases RG7304 Raf & MEK dual inh solid tumors RG7203 PDE10A inh schizophrenia RG7388 MDM2 ant solid & hem tumors RG7342 mglu5 PAM schizophrenia RG7446 PD-L1 MAb+Tarceva NSCLC EGFR+ RG7345 TAUpS422 MAb Alzheimer s RG7446 PD-L1 MAb+Zelboraf+/-cobimetinib m. melanoma RG7410 TAAR1 ago schizophrenia RG7446 PD-L1 MAb+Avastin+chemo solid tumors RG7893 Nav1.7 inh pain RG7446 PD-L1 MAb+cobimetinib solid tumors RG7800 SMN2 splicer spinal muscular atrophy RG7446 RG7446 RG7446 PD-L1 MAb+ipi/IFN PD-L1 MAb PD-L1 MAb+Gazyva solid tumors solid tumors lymphoma RG7935 RG3645 RG7716 a-synuclein MAb Parkinson's Disease Lucentis sust. deliv. AMD/RVO/DME VEGF-ANG2 MAb wamd New Molecular Entity (NME) Additional Indication (AI) RG7450 RG7597 RG7601 RG7601 RG7741 RG7775 Steap 1 ADC prostate ca. HER3/EGFR DAF+ cobi KRAS+ s. tumors venetoclax (Bcl-2)+ Gazyva CLL CLL venetoclax (Bcl-2) heme indications ChK1 inh solid tum & lymphoma MDM2 (4) IV prodrug AML Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other RG7787 RG7802 MSLN PE cfp CEA CD3 TCB solid tumors solid tumors RG-No Roche Genentech managed CHU Chugai managed RG7813 CEA IL2v solid tumors RG7841 ADC solid tumors RG7842 ERK inh solid tumors RG7876 CD40 imab+pd-l1 MAb solid tumors RG7882 ADC ovarian ca RG7888 OX40 MAb solid tumors 80 Status as of January 28, 2015

81 Roche Group development pipeline RG435 RG3502 RG6013 RG6046 RG7155 RG7221 RG7421 RG7440 RG7446 RG7446 RG7446 RG7596 ADC RG7599 RG7601 RG7601 RG7604 RG7686 RG1569 RG3637 RG6062 CHU RG7227 RG7745 RG7790 RG7929 RG7697 RG1577 RG1662 RG1678 RG7090 RG7314 RG7412 Phase II (23 NMEs + 12 Als) Avastin+Tarceva FIXa /FX bispecific MAb CSF-1R MAb Ang2-VEGF MAb cobimetinib ipatasertib (AKT inh) PD-L1 MAb PD-L1 MAb + Avastin polatuzumab vedotin (CD79bADC) hem tumors glypican-3 MAb Actemra danoprevir MAO-B inh bitopertin crenezumab obsessive compulsive dis. basimglurant (mglu5 NAM) V1 receptor antag solid tumors PD-L1 MAb bladder cancer 1/2l venetoclax (Bcl-2) C LL rel/refract 17pdel liver cancer systemic sclerosis lebrikizumab Esbriet SSc idiopathic interstitial pulmonary lung disease fibrosis IL-31R MAb Flu A MAb LptD antibiotic hemophilia A NSCLC 2 nd /3 rd line lifastuzumab vedotin (NaPi2bADC)Pt-resist. OC venetoclax (Bcl-2) taselisib (mutant-selective) setrobuvir GIP/GLP-1 dual ago GABRA5 NAM EGFR mut+ NSCLC PVNS/solid tumors colorectal cancer pictilisib RG7321 pictilisib solid tumors RG7601 RG3637 RG7929 CHU Kadcyla SERD venetoclax (Bcl-2)+ Rituxan lebrikizumab URAT 1 inh HER2+ NSCLC ER+(HER2-neg) mbc TNBC RCC DLBCL rel/ref FL solid tumors IPF atopic dermatitis HCV influenza HCV antibacterial type 2 diabetes gout Alzheimer s Down Syndrome TRD autism Alzheimer s RG435 1 RG435 RG1273 RG1273 RG1273 RG3502 RG3502 RG3502 RG3502 RG3502 RG7159 RG7159 RG7159 RG7204 RG7446 RG7446 RG7601 RG7601 RG7853 RG1569 RG3637 RG7413 CHU CHU RG1450 RG1594 RG1594 RG7417 Phase III (9 NMEs + 21 Als) Avastin Avastin Perjeta Perjeta lampalizumab (factor D) Status as of January 28, 2015 glioblastoma 1 st line RG435 1 Avastin ovarian cancer 1 st line RG435 1 Avastin rel. ovarian ca. Pt-sensitive NSCLC adj Perjeta HER2+ gastric cancer 1 st line Kadcyla +/- Perjeta HER2+ mbc 1 st l Gazyva Gazyva Gazyva Zelboraf alectinib (ALK inhibitor) Actemra lebrikizumab etrolizumab Actemra ocrelizumab ocrelizumab HER2+ mbc 2 nd line Kadcyla HER2+ gastric cancer 2 nd line Kadcyla Kadcyla + Perjeta Kadcyla + Perjeta DLBCL 1 st line inhl rituximab refractory follicular lymphoma 1 st line melanoma adj PD-L1 MAb NSCLC 2 nd line PD-L1 MAb bladder cancer 2 nd line venetoclax (Bcl-2) + Rit. CLL rel/ref IL-6R MAb gantenerumab HER2+ BC adj HER2+ BC adj HER2+ BC adj HER2+ BC neoadj venetoclax+gazyva (Bcl-2) CLL 1st line NSCLC giant cell arteritis severe asthma ulcerative colitis large-vessel vasculitis neuromyelitis optica Alzheimer s RMS PPMS geo. atrophy RG105 RG Registration (1 NME + 4 Als) MabThera SC RG435 2 Avastin recurrent cervical cancer Perjeta HER2+ BC neoadj RG7421 cobimetinib + Zelboraf m. melanoma RG Lucentis 1 US only : FDA submission decision pending 2 Approved in US, submitted in EU 3 Submitted in US New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other CLL diabetic retinopathy RG-No Roche Genentech managed CHU Chugai managed RG105 MabThera is branded as Rituxan in US and Japan RG1569 Actemra is branded as RoActemra in EU RG7159 Gazyva is branded as Gazyvaro in EU 81

82 NME submissions and their additional indications Projects currently in phase 2 and 3 gantenerumab (RG1450) Alzheimer s SERD (RG6046) ER+(HER2-neg) mbc MAO-B inh (RG1577) Alzheimer s FIXa /FX bispecific MAb (RG6013) hemophilia A GABRA5 NAM (RG1662) Down syndrome CSF-1R MAb (RG7155) PVNS and solid tumors bitopertin (RG1678) obsessive compulsive dis. Ang2-VEGF MAb (RG7221) colorectal cancer basimglurant (RG7090) depression ipatasertib AKT inh (RG7440) solid tumors V1 receptor antag (RG7314) autism polatuzumab vedotin (RG7596) CD79b ADC heme tumors crenezumab (RG7412) Alzheimer s lebrikizumab (RG3637) idiopathic pulmonary fibrosis ocrelizumab (RG1594) PPMS pictilisib PI3K inh (RG7321) solid tumors cobimetinib TNBC etrolizumab (RG7413) ulcerative colitis lebrikizumab (RG3637) severe asthma lifastuzumab (RG7599) NaPi2b ADC Pt resistant OC PDL-1 MAb (RG7446) combo Avastin RCC lampalizumab anti-factor D (RG7417) geo atrophy PDL-1 MAb (RG7446) bladder cancer taselisib (PI3Ki, RG7604) (mutant-selective) solid tumors venetoclax (Bcl-2i, RG7601) + Rituxan rel/ref FL danoprevir* (RG7227) HCV cobimetinib (MEK inh) combo Zelboraf met melanoma ocrelizumab (RG1594) RMS PD-L1 MAb (RG7446) NSCLC 2 nd /3 rd line venetoclax (Bcl-2i, RG7601) CLL rel/ref glypican-3 Mab (RG7686) liver cancer alectinib (RG7853) ALK-pos. NSCLC venetoclax (Bcl-2i, RG7601) + Gazyva CLL 1st line venetoclax (Bcl-2i, RG7601) + Gazyva DLBCL and beyond Flu A MAb (RG7745) influenza LptD antibiotic (RG7929) antibacterial Unless stated otherwise, submissions are planned to occur in US and EU * lead market China Status as of January 28, 2015 Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 82

83 Submissions of additional indications for existing products Projects currently in phase 2 and 3 Gazyva inhl rituximab refractory Gazyva follicular lymphoma 1 st line Zelboraf melanoma adj. Perjeta HER2-pos. gastric cancer 1L Lucentis (US) diabetic retinopathy *Avastin (US) ovarian cancer 1 st line *Avastin (US) rel. ovarian ca. Pt-sens Kadcyla+Perjeta HER2-pos. BC neoadj Kadcyla HER2-pos. NSCLC MabThera SC (EU) CLL Avastin +Tarceva(EU) EGFR mut+ NSCLC Gazyva DLBCL 1 st line Kadcyla+Perjeta HER2-pos. BC adj **Perjeta (EU) HER2-pos. BC neoadj *Avastin (US) rel. ovarian ca. Pt-resist Avastin (US) GBM Kadcyla +/- Perjeta HER2-pos mbc 1st line Perjeta HER2-pos. mbc 2 nd line Perjeta HER2-pos. BC adj Kadcyla HER2-pos. BC adj Avastin NSCLC adj **Avastin (EU) cervical cancer recurrent Kadcyla HER2-pos gastric cancer 2L Actemra giant cell arteritis Actemra systemic sclerosis and beyond Indicates submission to health authorities has occurred. * approved in EU; ** approved in US Unless stated otherwise, submissions are planned to occur in US and EU. Status as of January 28, 2015 Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 83

84 Major granted and pending approvals 2014 Approved Pending approvals US Avastin rel. ovarian ca. Pt-resist November 2014 Avastin cervical cancer August 2014 Esbriet* idiopathic pulmonary fibrosis October 2014 Xolair chronic idiopathic urticaria March 2014 cobimetinib + Zelboraf m. melanoma Filed December 2014 Lucentis diabetic retinopathy Filed August 2014 EU MabThera NHL sc formulation March 2014 RoActemra RA sc formulation April 2014 Avastin cervical cancer Filed April 2014 Gazyvaro CLL July 2014 RoActemra early RA September 2014 Perjeta BC neoadjuvant Filed September 2014 Avastin rel. ovarian ca. Pt-resist August 2014 Esbriet* idiopathic pulmonary fibrosis March 2011 cobimetinib + Zelboraf m. melanoma Filed September 2014 MabThera SC CLL Filed November 2014 Japan-Chugai alectinib ALECENSA ALK-pos rec/adv NSCLC July 2014 Zelboraf m. melanoma December 2014 Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 84 Status as of January 28, 2015 * Newly acquired asset (Intermune)

85 Doing now what patients need next